NO20074332L - Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser - Google Patents

Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser

Info

Publication number
NO20074332L
NO20074332L NO20074332A NO20074332A NO20074332L NO 20074332 L NO20074332 L NO 20074332L NO 20074332 A NO20074332 A NO 20074332A NO 20074332 A NO20074332 A NO 20074332A NO 20074332 L NO20074332 L NO 20074332L
Authority
NO
Norway
Prior art keywords
nervous system
central nervous
preparation
treatment
system disorders
Prior art date
Application number
NO20074332A
Other languages
English (en)
Other versions
NO340257B1 (no
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NO20074332L publication Critical patent/NO20074332L/no
Publication of NO340257B1 publication Critical patent/NO340257B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Den foreliggende oppfinnelse tilveiebringer en fremgangsmåte og et preparat for behandling av en sentralnervesystemforstyrrelse hos et pattedyrindivid, som omfatter administrering av en effektiv mengde av en 11-deoksyprostaglandinforbindelse til et individ som trenger det. Oppfinnelsen tilveiebringer også nye 11-deoksyprostaglandinforbindelser.
NO20074332A 2005-01-27 2007-08-24 11-deoksyprostaglandinforbindelse og anvendelse derav til fremstilling av et preparat for behandling av en sentralnervesystemforstyrrelse hos et pattedyrindivid NO340257B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64700805P 2005-01-27 2005-01-27
PCT/JP2006/301704 WO2006080549A2 (en) 2005-01-27 2006-01-26 Method and composition for treating central nervous system disorders

Publications (2)

Publication Number Publication Date
NO20074332L true NO20074332L (no) 2007-10-17
NO340257B1 NO340257B1 (no) 2017-03-27

Family

ID=36740907

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074332A NO340257B1 (no) 2005-01-27 2007-08-24 11-deoksyprostaglandinforbindelse og anvendelse derav til fremstilling av et preparat for behandling av en sentralnervesystemforstyrrelse hos et pattedyrindivid

Country Status (19)

Country Link
US (2) US8202909B2 (no)
EP (2) EP2332545A1 (no)
JP (1) JP5147404B2 (no)
KR (1) KR101354771B1 (no)
CN (1) CN101146541B (no)
AR (1) AR055846A1 (no)
AU (1) AU2006209072B2 (no)
BR (1) BRPI0607084A2 (no)
CA (1) CA2595898C (no)
DK (1) DK1841433T3 (no)
ES (1) ES2375082T3 (no)
IL (1) IL184578A (no)
NO (1) NO340257B1 (no)
NZ (1) NZ556710A (no)
PL (1) PL1841433T3 (no)
PT (1) PT1841433E (no)
RU (1) RU2440338C2 (no)
TW (1) TWI384988B (no)
WO (1) WO2006080549A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
JP2010519177A (ja) * 2007-02-27 2010-06-03 スキャンポ・アーゲー ミトコンドリアを保護するための組成物および方法
WO2009011449A2 (en) 2007-07-19 2009-01-22 R-Tech Ueno, Ltd. Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US9084815B2 (en) 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
IN2013MN00733A (no) * 2010-10-15 2015-06-12 Scinopharm Kunshan Biochemical Technology Co Ltd
CA2860453C (en) * 2011-01-24 2020-04-28 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
US20120270945A1 (en) * 2011-04-19 2012-10-25 Sucampo Ag Method for modulating cytokine activity
AU2012293157A1 (en) * 2011-08-05 2014-03-13 Sucampo Ag Method for treating schizophrenia
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
CA2965047C (en) * 2014-10-21 2018-06-26 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120243A (en) * 1970-03-09 1968-07-17 Samuelsson Bengt Improvements in or relating to unsaturated carboxylic acid derivatives and the manufacture thereof
BE786215A (fr) * 1971-07-14 1973-01-15 American Cyanamid Co Nouveaux composes apparentes aux prostaglandines naturelles et procedesde leur preparation
ZA764727B (en) * 1975-09-02 1977-07-27 Upjohn Co Prostanoic acid derivatives
SU845774A3 (ru) 1976-04-20 1981-07-07 Фармиталия Карло Эрба С.П.А. (Фирма) Способ получени 13,14-дегидро-11-дЕзОКСипРОСТАглАНдиНОВ
US4131738A (en) * 1977-07-05 1978-12-26 The Upjohn Company 6-Hydroxy-PGE1 compounds
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2037009C (en) 1990-02-26 1998-01-27 Ryuji Ueno 15-dehydroxy-16-oxoprostaglandins
TW224942B (no) 1990-04-04 1994-06-11 Adka Ueno Kk
JPH04187637A (ja) * 1990-11-21 1992-07-06 Ueno Seiyaku Oyo Kenkyusho:Kk 記憶改善剤
JPH07113012B2 (ja) 1991-01-29 1995-12-06 株式会社アールテック・ウエノ 新規１５−ケト−プロスタグランジン類
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6242485B1 (en) 1996-06-10 2001-06-05 R-Tech Ueno Endothelin antagonist
EP0978284B1 (en) 1997-11-28 2008-07-23 Sucampo AG Use of 15-keto-prostaglandin-e compounds as endothelin antagonists
JP3703004B2 (ja) * 1998-07-15 2005-10-05 小野薬品工業株式会社 ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体
AU3713600A (en) * 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
CA2403086C (en) * 2000-03-24 2010-08-17 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
US20040224995A1 (en) 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
CN1214794C (zh) * 2003-09-08 2005-08-17 秦正红 前列腺素a1在制备治疗脑缺血性中风疾病的药物中的用途

Also Published As

Publication number Publication date
TW200642690A (en) 2006-12-16
IL184578A0 (en) 2007-10-31
JP2008528440A (ja) 2008-07-31
EP1841433B1 (en) 2011-11-30
BRPI0607084A2 (pt) 2009-08-04
EP2332545A1 (en) 2011-06-15
RU2440338C2 (ru) 2012-01-20
RU2007132081A (ru) 2009-03-10
NO340257B1 (no) 2017-03-27
DK1841433T3 (da) 2012-01-16
PL1841433T3 (pl) 2012-07-31
US20060194880A1 (en) 2006-08-31
PT1841433E (pt) 2012-02-01
NZ556710A (en) 2010-08-27
KR101354771B1 (ko) 2014-01-22
WO2006080549A2 (en) 2006-08-03
ES2375082T3 (es) 2012-02-24
JP5147404B2 (ja) 2013-02-20
CA2595898C (en) 2015-04-28
CN101146541A (zh) 2008-03-19
AR055846A1 (es) 2007-09-12
US8202909B2 (en) 2012-06-19
EP1841433A2 (en) 2007-10-10
HK1118716A1 (en) 2009-02-20
AU2006209072B2 (en) 2011-02-24
TWI384988B (zh) 2013-02-11
US20120225938A1 (en) 2012-09-06
CA2595898A1 (en) 2006-08-03
AU2006209072A1 (en) 2006-08-03
IL184578A (en) 2015-02-26
KR20070107065A (ko) 2007-11-06
CN101146541B (zh) 2012-04-11
WO2006080549A3 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA200900783A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
HRP20050826B1 (hr) Ciklički inhibitori proteinske tirozin kinaze
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
NO20092612L (no) Forbindelser og metode for kinasemodulering og indikasjoner for dette
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees